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Abstract
We assessed the impact of smoking on response to epidermal growth factor receptor (EGFR)etyrosine kinase
inhibitors (TKIs) in advanced nonesmall-cell lung cancer EGFR-mutant patients incorporating 9 studies that
involved 1029 patients. Nonsmokers had longer progression-free survival than ever smokers after EGFR-TKI
treatment. Smoking history should be considered an essential factor in studies regarding EGFR-targeted
agents toward EGFR mutants.
Background: The strong association between smoking history and the presence of epidermal growth factor receptor
(EGFR) mutations has been proven in nonesmall-cell lung cancer (NSCLC), which explains the favorable response to
EGFRetyrosine kinase inhibitor (EGFR-TKI) therapy in nonsmoking NSCLC patients. However, few studies directly focus
on the relationship between EGFR-TKI’s efﬁcacy and smoking history in NSCLC EGFR-mutant patients. Methods:
Electronic databases were searched for eligible literatures. Data on objective response rates, disease control rates, and
progression-free survival (PFS) stratiﬁed by smoking status were extracted and synthesized on the basis of a random-
effect model. Subgroup and sensitivity analyses were conducted. Results: A total of 9 studies that involved a total of
1029 EGFR-mutant advanced NSCLC patients after EGFR-TKI treatment were included. In overall, nonsmoking was
associated with signiﬁcant prolonged PFS (HR, 0.73, 0.60 to 0.88; P ¼ .001) compared to ever smokers. However, only
marginal improvements without statistical signiﬁcance in objective response rates (odds ratio, 1.11; 95% conﬁdence
interval, 0.85 to 1.46; P ¼ .433) and disease control rate (odds ratio, 1.04; 95% conﬁdence interval, 0.82 to 1.33; P ¼
.740) were observed. Subgroup analyses showed that the beneﬁts of PFS in nonsmokers were predominantly presented
in pooled results of studies enrolling patients with active EGFR mutations, studies involving previously treated patients,
and retrospective studies. Additionally, we failed to observe any signiﬁcant beneﬁt from nonsmokers in every subgroup
for objective response rates and disease control rate. Conclusion: For advanced NSCLC patients with EGFRmutations,
nonsmoking is associated with longer PFS than ever smoking after EGFR-TKIs treatment. Smoking history should be
considered an essential factor in studies regarding EGFR-targeted agents toward EGFR-mutant patients.
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Lung cancer tops the list of cancer-related death all over the
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disease for its unique clinical characteristics.3 Remarkable sex and
geographic bias had been recognized in female Asian patients for
higher incidence of nonsmoking related nonesmall-cell lung cancer
(NSCLC).4-6 Recently, a dramatically better therapeutic response
to epidermal growth factor receptoretyrosine kinase inhibitors
(EGFR-TKIs) has been demonstrated in this subset of NSCLC
patients.7-9 These signiﬁcant observations possibly result from
higher occurrence rate of EGFR mutations in these patients.10-13
By far, the frequency of activating EGFR mutations including
exon 19 in-frame deletions (exon 19 del) and exon 21 L858R
substitution (exon 21 L858R) has been reported to be 40% to
60% in nonsmoking patients compared to 10% to 20% in
tobacco-associated patients for NSCLC.10-13 Moreover, it is
believed that the dose of tobacco smoke exposure is inversely
associated with the rate of EGFR mutations.14,15 Similarly, all
these ﬁndings might suggest that favorable response to EGFR-TKI
therapy in nonsmoking NSCLC patients is due to their higher
EGFR-mutant rate.16 Although a strong association between
smoking history and the presence of EGFR mutations has been
proven, few studies directly focus on the relationship between
EGFR-TKI’s response and cigarette smoking history in NSCLC
EGFR-mutant patients. Notably, a latest retrospective study
showed that over 30 pack-years of cigarette smoking was an in-
dependent negative predictive factor of EGFR-TKI treatment
outcome in lung adenocarcinoma patients with activating EGFR
mutations.17
However, it is still unclear whether the efﬁcacy of EGFR-TKIs
for NSCLC is associated with smoking status in EGFR-mutant
patients. A comprehensive analysis of all the subgroup data from
previous studies is warranted. Thus, we sought to perform a meta-
analysis incorporating all available evidence to evaluate the clinical
outcome according to smoking status in advanced NSCLC patients
with EGFR mutations after the treatment with EGFR-TKIs.Figure 1 Flow Chart of Study Selection
Abbreviations: CI ¼ conﬁdence interval; EGFR-TKI ¼ epidermal growth factor receptoretyrosine kinMaterial and Methods
Literature Search
All relevant articles were retrieved by searching through PubMed,
Embase, and the Central Registry of Controlled Trials of the
Cochrane Library using a combination of the terms “EGFR,”
“epidermal growth factor receptor,” “mutation,” “lung,” “none
small-cell lung cancer,” “NSCLC,” “tyrosine kinase inhibitor” and
“TKI.” An additional search through Google Scholar and a manual
search through reference lists of pertinent reviews were additionally
performed. Two authors (Z.Y. and K.S.) carried out the search
independently. No language or date restrictions were set in the
search.
Inclusion and Exclusion Criteria
Eligible studies had to meet the following criteria: (1) clinical
trials or retrospective studies that investigate or report advanced
NSCLC patients with EGFR mutations after EGFR-TKI treat-
ment that were not used as combined therapy or maintenance
therapy; (2) clinical outcomes stratiﬁed by smoking status; (3) pri-
mary outcome available. Studies failing to meet the inclusion criteria
were excluded.
Outcomes Measures, Data Extraction, and Quality
Assessment
The primary outcome for this meta-analysis was progression-free
survival (PFS). Data of PFS were extracted as hazard ratios (HRs) of
nonsmokers compared to ever smokers in EGFR-mutant patients
using EGFR-TKIs and its 95% conﬁdence interval (CI) from
subgroup analysis. We used median PFS and the P value to calculate
the HR and its 95% CI, then reviewed them with Review Manager
(version 5.1 for Windows; the Cochrane Collaboration, Oxford,
UK) if they were not displayed directly. Other outcomes were
objective response rate (ORR) and disease control rate (DCR). Thease inhibitor; HR ¼ hazard ratio; PFS ¼ progression-free survival.
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Table 1 Characteristics of Studies Included in Meta-analysis
Study (Year of
Publication) EGFR-TKIs Patient Status
Study
Type Exon of EGFR Mutation
Smoking Status
(Sample Size) ORR (%) DCR (%)
Median PFS
(Months)
P Value
of PFS
HR for PFS
(95% CI)a
Asahinab (2006)21 Geﬁtinib CT naive Pro Exon 19 del and exon 21 L858R NS
(n ¼ 13)
11/13 (84.6) 12/13 (92.3) 8.3 .499 0.589 (0.123-2.815)
ES
(n ¼ 3)
1/3 (33.3) 1/3 (33.3) 0.9
Rosell (2009)22 Erlotinib CT naive or
previously treated
Pro Exon 19 del and exon 21 L858R NS
(n ¼ 138)
102/138 (73.9) 126/138 (91.3) NA NA 0.975 (0.436-2.179)
ES
(n ¼ 59)
37/59 (62.7) 51/59 (86.4) NA
Won (2011)24 Geﬁtinib or
erlotinib
CT naive or
previously treated
Retro Exon 19 del and exon 21 L858R NS
(n ¼ 68)
48/68 (70.6) 62/68 (91.2) NA NA 0.787 (0.440-1.408)
ES
(n ¼ 19)
7/19 (36.8) 15/19 (78.9) NA
Kim (2014)17 Geﬁtinib or
erlotinib
CT naive or
previously treated
Retro Exon 19 del and exon 21 L858R NS
(n ¼ 145)
90/145 (62.1) 133/145 (91.7) NA NA 0.657 (0.376-1.146)
ES
(n ¼ 77)
43/77 (55.8) 69/77 (89.6) NA
Lim (2014)27 Geﬁtinib or
erlotinib
CT naive or
previously treated
Retro Exon 19 del and exon 21 L858R NS
(n ¼ 154)
NA NA 11.1 .012 0.703 (0.534-0.925)
ES
(n ¼ 88)
NA NA 7.8
Chou (2005)20 Geﬁtinib CT naive or
previously treated
Retro Exon 19 del and exon 21 L858R and
nonclassical mutations
NS
(n ¼ 25)
NA NA 6.0 .932 1.104 (0.114-10.654)
ES
(n ¼ 8)
NA NA 7.3
Xub (2009)23 Geﬁtinib CT naive or
previously treated
Retro Exon 19 del and exon 21 L858R and
nonclassical mutations
NS
(n ¼ 25)
17/25 (68.0) 25/25 (100.0) 8.5 .773 1.247 (0.276-5.646)
ES
(n ¼ 7)
6/7 (85.7) 7/7 (100.0) 8.0
Choi (2014)25 Geﬁtinib or
erlotinib
CT naive Retro Exon 19 del and exon 21 L858R and
nonclassical mutations
NS
(n ¼ 100)
76/100 (76.0) 95/100 (95.0) NA .32 0.80 (0.51-1.25)
ES
(n ¼ 30)
27/30 (90.0) 30/30 (100.0) NA
Fukihara (2014)26 Geﬁtinib or
erlotinib
CT naive or
previously treated
Retro Exon 19 del and exon 21 L858R and
nonclassical mutations
NS
(n ¼ 42)
NA NA 12.8 .080 0.539 (0.270-1.077)
ES
(n ¼ 28)
NA NA 6.9
Abbreviations: CI ¼ conﬁdence interval; CT ¼ chemotherapy (not speciﬁc); DCR ¼ disease control rate; EGFR-TKIs ¼ epidermal growth factor receptoretyrosine kinase inhibitors; ES ¼ ever smoker; Exon 19 del ¼ exon 19 in-frame deletions; Exon 21 L858R ¼ exon 21 L858R
substitution; HR ¼ hazard ratio; NA ¼ not available; NS ¼ nonsmoker; ORR ¼ objective response rate; PFS ¼ progression-free survival; Pro ¼ prospective; Retro ¼ retrospective.
aHR represents HRnonsmoker/ever smoker in EGFR-mutant cohort using EGFR-TKIs.
bWe considered time to progression as PFS in the studies of Asahina et al21 and Xu et al.23
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Yaxiong Zhang et aldata collection and assessment of methodological quality followed
the Quorum and the Cochrane Collaboration guidelines (http://
www.cochrane.de). The data on lead author, drug, patient status,
study category, exon of EGFR mutation, smoking status, ORR,
DCR, and PFS were extracted by 2 investigators (F.W. and L.W.)
independently. Three reviewers (H.S., Q.T., and T.Y.) used a
modiﬁed Newcastle-Ottawa scale to assess all the prospective and
retrospective studies. Discrepancies were discussed by all in-
vestigators to reach a consensus.
Statistical Analysis
HRs for PFS and odds ratios (ORs) for dichotomous data (ORR
and DCR) with 95% CI were pooled. Heterogeneity across studies
was assessed with a forest plot and the inconsistency statistic (I2).
The random-effects model was used in case of potential heteroge-
neity and to avoid underestimation of standard errors of pooled
estimates in our meta-analyses. All calculations were performed by
Stata 11.0 (StataCorp, College Station, TX). Subgroup analysis was
conducted according to EGFR mutation site, study type, and
treatment line, respectively. An OR value of greater than 1 reﬂected
a better ORR or DCR in nonsmokers, while a HR value of less than
1 stood for more beneﬁt from EGFR-TKIs in terms of PFS for
nonsmoking patients. All CIs had 2-sided probability coverage of
95%. A statistical test with a P value of less than .05 was considered
as signiﬁcant.
Publication Bias
An extensive search strategy was made to minimize the potential
of publication bias. Graphical funnel plots were generated to visually
assess a publication bias. The statistical methods used to detect
funnel plot asymmetry were the rank correlation test of Begg and
Mazumdar and the regression asymmetry test of Egger.18,19
Results
Eligible Studies
A total of 543 records were identiﬁed according to the search
strategy, and we ﬁnally enrolled 9 studies17,20-27 involving 1029
chemonaive or previously treated advanced NSCLC patients with
EGFR mutations that referred to the efﬁcacy of EGFR-TKIs
(geﬁtinib or erlotinib) stratiﬁed by smoking status. Figure 1 pro-
vides the ﬂow chart. Former or current smokers were categorized
as ever smokers (n ¼ 710), while the rest of patients were cate-
gorized as nonsmokers (n ¼ 319). Data of ORR and DCR were
not available in 3 studies,20,26-27 so they were excluded from
related analysis. Additionally, we considered time to progression as
PFS in the studies by Asahina et al21 and Xu et al.23 Table 1
summarizes the characteristics of the involved studies for meta-
analysis.
Meta-analyses of Nonsmokers Versus Ever Smokers in
Terms of ORR, DCR, and PFS
Overall, when compared to the ever smoker group, the
nonsmoker group was associated with signiﬁcantly longer PFS (HR,
0.73; 95% CI, 0.60 to 0.88; P ¼ .001; Figure 2C). However,
although some improvement in ORR (OR 1.11; 95% CI, 0.85 to
1.46; P ¼ .433; Figure 2A) were observed, the beneﬁts did not
reach statistical signiﬁcance. Additionally, there was no signiﬁcantdifference in DCR (OR 1.04; 95% CI, 0.82 to 1.33; P ¼ .740;
Figure 2B) between nonsmokers and ever smokers.
Subgroup Analyses, Sensitivity Analyses, and
Publication Bias
When stratifying patients according to EGFR mutation site, we
observed that greater beneﬁts of nonsmoking patients were pre-
sented in active EGFR mutations’ cohort (exon 19 del and exon 21
L858R) than the cohort with a mixture of active and nonclassical
EGFR mutations regarding PFS (active mutations vs. active and
nonclassical mutations: HR, 95% CI, P value of .72, .58 to .89,
.003 vs, .74, .52 to 1.07, .106) (Figure 3C). Similar results of
signiﬁcant beneﬁts of PFS in nonsmokers were found in subgroup
analysis involving retrospective studies (retrospective studies vs.
prospective studies: HR, 95% CI, P value of .72, .59 to .87, .001
vs. .88, .43 to 1.79, .720) or chemotherapy-naive patients
(chemotherapy-naive vs. chemotherapy-naive and previously
treated: HR, 95% CI, P value of .71, .58 to .88, .001 vs. .78, .51
to 1.20, .263) (Figure 3C). In terms of ORR and DCR, we failed
to observe any signiﬁcant beneﬁts from nonsmokers in each sub-
group (Figure 3A, B). As a result, the conclusions regarding all
outcomes did not alter. All results from the above subgroups and
sensitivity analyses are summarized in Supplemental Table 1 in the
online version. With regard to the publication bias, no signiﬁcant
bias was observed for all outcomes through both Begg’s test and
Egger’s test (P > .05).
Discussion
For advanced NSCLC patients with EGFR mutations, the asso-
ciation of smoking history and efﬁcacy of EGFR-TKIs therapy re-
mains unclear. A meta-analysis incorporating all available data from
correlative studies is a good way to address this question. We
conducted this study and found that nonsmoking patients had
signiﬁcant reduced disease progression risk than ever smokers after
receipt of EGFR-TKIs. Additionally, favorable outcome of ORR in
nonsmokers was found, but the statistical signiﬁcance was not
approached.
Our results derived the following interpretations. First, smoking-
related lung cancer is caused by multiple carcinogenic mechanisms
through many genotoxic or inﬂammatory compounds in cigarette
smoke, which makes a complex framework of carcinogenesis of
lung.28 Thus, EGFR mutation might be one of carcinogenic routes
of NSCLC in smoking patients, but it is not a single activated
signaling pathway. EGFR-TKI might be effective for patients with
EGFR mutation at the beginning of treatment, but it could not
block other carcinogenic pathways induced by cigarette smoke. This
could be the reason why the only signiﬁcant difference in terms of
PFS was found between nonsmokers and ever smokers instead of
ORR or DCR. The dominant carcinogenic effect of EGFR muta-
tion might be replaced by other critical growth regulatory genes,
most frequently KRAS and TP53,29,30 during the process of EGFR-
TKI therapy, which resulted in disease progression after a period of
treatment.
Additionally, cigarette smoke exposure not only stimulates
induced aberrant EGFR phosphorylation, thus impairing receptor
degradation, but also resulted in a different EGFR conformation and
signaling that were resistant to TKIs in the TKI-sensitive EGFRClinical Lung Cancer March 2015 - 147
Figure 2 Meta-Analyses of Nonsmoker Versus Ever Smoker in EGFR-Mutant NoneSmall-Cell Lung Cancer Patients Receiving
EGFR-TKIs for (A) ORR, (B) DCR, and (C) PFS
Abbreviations: CI ¼ conﬁdence interval; DCR ¼ disease control rate; EGFR-TKI ¼ epidermal growth factor receptoretyrosine kinase inhibitor; HR ¼ hazard ratio; OR ¼ odds ratio; ORR ¼ objective
response rate; PFS ¼ progression-free survival.
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Figure 3 Subgroup Analyses of Nonsmoker Versus Ever Smoker in EGFR-Mutant NoneSmall-Cell Lung Cancer Patients Receiving
EGFR-TKIs (Number of Studies) for (A) ORR, (B) DCR, and (C) PFS
Abbreviations: CI ¼ conﬁdence interval; DCR ¼ disease control rate; EGFR-TKI ¼ epidermal growth factor receptoretyrosine kinase inhibitor; HR ¼ hazard ratio; OR ¼ odds ratio; ORR ¼ objective
response rate; PFS ¼ progression-free survival.
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150 -mutants.31 Moreover, other research demonstrated that TKI resis-
tance in exon 21 L858R mutant NSCLC cells after exposure to
cigarette smokeeinduced oxidative stress was due to structural
alteration of EGFR upon binding of active c-Src to the receptor.32
Interestingly, this could be eliminated with Src inhibition in vitro,
which offered a new rationale for using Src inhibitors to treat TKI-
resistant NSCLC patients with exon 21 L858R mutation in
smokers.32 It also explained the result from subgroup analysis that
nonsmokers received a signiﬁcant PFS beneﬁt only in the active
EGFR-mutant cohort with a larger proportion of exon 21 L858R,
instead of the active and nonclassical EGFR-mutant cohort.
Notably, this is the ﬁrst study to comprehensively address the
effect of smoking on response to EGFR-TKIs in patients with
advanced NSCLC with EGFR mutations. Nevertheless, there exist
several limitations. First, our meta-analysis was mostly based on
subgroup data extracted from prospective and retrospective studies,
which compromised the evidence level. However, considering the
strict eligibility criteria, 2 prospective and 7 retrospective studies
were all that we could enroll to extract relevant data. Second, the
majority of the included patients were Asians with data extracted
from retrospective reports, which might lead to overlap of patient
data. However, the patients of each retrospective study were
enrolled from different medical centers, which minimized this
possibility. Third, ORR and DCR data were not available in all the
included studies, which might inﬂuence statistical signiﬁcance in
pooled analyses of ORR and DCR, as well as subgroup analyses. In
addition, almost all the eligible articles failed to provide data
regarding overall survival of ever smokers and never smokers, so we
had to compromise to conduct our study. In addition, we could not
evaluate the respective effect of different EGFR-TKIs because we
lacked enough data. Further studies are warranted to provide more
complete information.
Despite these limitations, our comprehensive analysis has statis-
tically conﬁrmed that nonsmoking patients with EGFR mutations
have longer PFS for EGFR-TKIs treatment compared to patients
with EGFR mutations who have a smoking history. The result leads
to some important suggestions. First, investigators should consider
the proportion of smoking patients as a stratiﬁcation factor in
designing or reviewing clinical studies involving TKI therapy pa-
tients with EGFR mutations. Second, the response to EGFR-TKIs
in smoking EGFR-mutant patients is worse, so extra treatment,
such as Src inhibitors or antioxidants combined with TKIs, may be
needed in smoking patients to prolong survival. Finally, further
efforts should be made to investigate the mechanisms of EGFR-
TKIs’ resistance induced by cigarette smoke in different genotypes
of EGFR mutants in order to ﬁnd solutions.
In conclusion, for advanced NSCLC patients with EGFR mu-
tations, nonsmoking is associated with longer PFS than ever
smoking after EGFR-TKIs treatment. Smoking history should be
considered an essential factor in studies regarding EGFR-targeted
agents toward EGFR-mutant patients.
Clinical Practice Points
 The strong association between smoking history and the pres-
ence of EGFR mutations has been proven in NSCLC, which
explains the favorable response to EGFR-TKI therapy in
nonsmoking NSCLC patients. However, few studies haveClinical Lung Cancer March 2015directly focused on the relationship between EGFR-TKI’s efﬁ-
cacy and smoking history in NSCLC EGFR-mutant patients.
Therefore, we performed a metaanalysis incorporating all avail-
able evidence to evaluate the clinical outcome according to the
smoking status in advanced NSCLC patients with EGFR mu-
tations after treatment with EGFR-TKIs.
 Our comprehensive analysis conﬁrmed that nonsmoking
EGFRmutant patients have signiﬁcant reduced disease progres-
sion risk than ever smokers after receipt of EGFR-TKIs.
 Ours is the ﬁrst study to comprehensively address the impact of
smoking on response to EGFR-TKIs in advanced NSCLC with
EGFR mutations.
 Our results indicate that ﬁrst, we investigators should consider
the proportion of smoking patients as a stratiﬁcation factor in
designing or reviewing clinical studies involving TKIs therapy in
EGFR mutants. Second, the response to EGFR-TKIs in smoking
EGFR-mutant patients is worse, so extra treatment, such as Src
inhibitors or antioxidants combined with TKIs, may be needed
in smoking patients to prolong survival.
 Finally, further efforts should be made to investigate the mech-
anisms of EGFR-TKIs’ resistance induced by cigarette smoke in
different genotypes of EGFR mutants in order to ﬁnd solutions.Acknowledgments
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Table S1 Summary of Subgroup Analyses Results
Outcome Subgroup/Total
No. of
Studies OR/HRa (95% CI)
Effect Size Heterogeneity
Z P Value P Value I 2 (%)
ORR Exon 19 del and exon 21 L858R 4 1.225 (0.898-1.671) 1.28 .201 .701 0.0
Exon 19 del and exon 21 L858R and
nonclassical mutations
2 0.835 (0.486-1.433) 0.66 .512 .930 0.0
Prospective 2 1.214 (0.756-1.952) 0.80 .422 .539 0.0
Retrospective 4 1.069 (0.771-1.482) 0.40 .690 .510 0.0
Chemotherapy naive 2 0.901 (0.504-1.611) 0.35 .725 .383 0.0
Chemotherapy naive or previously treated 4 1.180 (0.871-1.599) 1.07 .285 .689 0.0
Total 6 1.114 (0.851-1.458) 0.78 .433 .718 0.0
DCR Exon 19 del and exon 21 L858R 4 1.067 (0.810-1.405) 0.46 .647 .875 0.0
Exon 19 del and exon 21 L858R and
nonclassical mutations
2 0.959 (0.570-1.614) 0.16 .876 .939 0.0
Prospective 2 1.091 (0.704-1.691) 0.39 .697 .438 0.0
Retrospective 4 1.021 (0.762-1.369) 0.14 .890 .983 0.0
Chemotherapy naive 2 1.008 (0.574-1.769) 0.03 .979 .394 0.0
Chemotherapy naive or previously treated 4 1.050 (0.801-1.376) 0.35 .723 .994 0.0
Total 6 1.042 (0.817-1.330) 0.33 .740 .975 0.0
PFS Exon 19 del and exon 21 L858R 5 0.721 (0.581-0.895) 2.96 .003 .934 0.0
Exon 19 del and exon 21 L858R and
nonclassical mutations
4 0.743 (0.518-1.066) 1.61 .106 .682 0.0
Prospective 2 0.878 (0.429-1.795) 0.36 .720 .575 0.0
Retrospective 7 0.717 (0.592-0.869) 3.39 .001 .941 0.0
Chemotherapy naive 2 0.782 (0.508-1.203) 1.12 .263 .712 0.0
Chemotherapy naive or previously treated 7 0.715 (0.582-0.878) 3.20 .001 .912 0.0
Total 9 0.727 (0.604-0.875) 3.37 .001 .968 0.0
Abbreviations: CI ¼ conﬁdence interval; DCR ¼ disease control rate; Exon 19 del ¼ exon 19 in-frame deletions; Exon 21 L858R ¼ exon 21 L858R substitution; HR ¼ hazard ratio; OR ¼ odds ratio;
ORR ¼ objective response rate; PFS ¼ progression-free survival.
aOR/HR represents OR/HR non-smoker/ever-smoker in EGFR mutants cohort using EGFR-TKIs.
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